Plain-English translation of NCT06407947 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a treatment called CT071 Injection, which uses your own immune cells that have been specially modified in a laboratory to help fight multiple myeloma — a serious blood cancer. The study will evaluate whether this treatment is safe and how well it works in patients who have been newly diagnosed with a high-risk form of the disease.
Multiple myeloma is a serious cancer, and patients with high-risk forms face poorer outcomes with standard treatments. Researchers are exploring this new approach using modified immune cells because they believe it may offer a more powerful way to fight the disease and help patients live longer, healthier lives.
You likely qualify if…
You likely don't qualify if…
If you enroll, doctors will collect your immune cells through a special blood collection process. These cells will be sent to a laboratory where they are modified to better recognize and attack cancer cells, then returned to you for infusion back into your bloodstream. The trial will track your health closely with blood tests and scans to monitor how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai Changzheng Hospital
Collaborators
CARsgen Therapeutics Co., Ltd.
Enrollment target
~10 participants
Started
June 2024
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.